Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP045052priorityCriticalpatent/ECSP045052A/en
Publication of ECSP045052ApublicationCriticalpatent/ECSP045052A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se proporciona una composición farmacéutica para el tratamiento de condiciones en mamíferos que son sensibles a inhibición de COX-2 que comprende en combinación un inhibidor de COX-2 y aspirina a dosis baja para uso simultáneo, secuencial o separado.A pharmaceutical composition is provided for the treatment of conditions in mammals that are sensitive to COX-2 inhibition comprising in combination a COX-2 inhibitor and low dose aspirin for simultaneous, sequential or separate use.
ECSP0450522004-04-082004-04-08
COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS
ECSP045052A
(en)
Use of a composition comprising an h1 antagonist, and an anti-tnf alpha compound to treat allergic conjunctivitis or allergic rhinitis in a human subject
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
Compounds derived from quinoline or benzopyran hiv replication inhibitors; pharmaceutical composition comprising said compounds; and its use in the treatment of a hiv infection
A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
Compounds derived from nitrogen heterocycles, antagonists of apoptosis protein inhibitors; its pharmaceutical compositions; and use of said compounds for the treatment of cancer.
Pharmaceutical formulation for topical application on the skin comprising an oil-in-water emulsion and the compound (r) -3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) - 1h-pyrazol-1-yl] propanonitrile, jak1 / jak2 inhibitor; method to treat a skin disorder; and its use in the treatment of a skin disorder.
Use of a combination of an epoxy ketone peptide proteasome inhibitor or an acceptable pharmaceutical salt thereof, and one or more other therapeutic agents to treat cancer.
Compounds derived from resolviin; pharmaceutical composition; use of the composition; pharmaceutical kit; pharmaceutical combination; use of the compounds in the treatment and / or prevention of an ophthalmic condition.
A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
Compounds derived from 6-phenyl-1h-imidazo [4,5-c] pyridine-4-carbonitrile, inhibitors of cathepsin s and cathepsin k; pharmaceutical composition; and use in the treatment of osteoporosis, atherosclerosis, inflammation, among other diseases.